No Impact of KIF6 Genotype on Vascular Risk and Statin Response Among 18,348 Randomized Patients in the Heart Protection Study
Authors:
- Jemma C. HopewellJHJemma C. Hopewell
- Sarah ParishSPSarah Parish
- Robert ClarkeRCRobert Clarke
- Jane ArmitageJAJane Armitage
- Louise BowmanLBLouise Bowman
- Jorg HagerJHJorg Hager
- Mark LathropMLMark Lathrop
- Rory CollinsRCRory Collins
Abstract
No abstract availableKeywords
Funding Information
- Merck and Company
This publication has 35 references indexed in Scilit:
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic StudiesPLOS ONE, 2009
- Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapyCurrent Opinion in Lipidology, 2007
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatinJACC, 2000
- Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosisThe American Journal of Cardiology, 1999
- Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug researchPharmacogenetics, 1998
- The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 1998